ropinirole has been researched along with MPTP Neurotoxicity Syndrome in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bladder hyperreflexia is a common non-motor feature of Parkinson's disease." | 1.46 | Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia. ( Benham, CD; Chaudhuri, KR; Hikima, A; Iravani, MM; Jackson, MJ; Jenner, P; Lione, L; Pritchard, S; Rose, S, 2017) |
| "Ropinirole (1." | 1.40 | Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats. ( Bisht, R; Gupta, H; Kaur, B; Prakash, A, 2014) |
| " Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metabolism and increases bioavailability in the brain." | 1.39 | Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice. ( Chen, JC; Hsieh, YT; Kuo, YH; Lao, CL, 2013) |
| "Ropinirole is a pharmacologically active agent used in the treatment of Parkinson's disease (PD) that directly acts on dopamine receptors." | 1.39 | Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. ( Oh, MS; Park, G; Park, YJ; Yang, HO, 2013) |
| "Ropinirole was weakly neuroprotective in this model." | 1.32 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. ( Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L, 2004) |
| " Chronic administration of ropinirole for 21 days produced a statistically significant increase in motor activity compared to the initial administration, and akinesia scores, measured through rating the quality of movements, were also improved without obvious dyskinesia." | 1.31 | Effects of ropinirole on motor behavior in MPTP-treated common marmosets. ( Fukuzaki, K; Kamenosono, T; Kitazumi, K; Nagata, R, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pritchard, S | 1 |
| Jackson, MJ | 2 |
| Hikima, A | 1 |
| Lione, L | 1 |
| Benham, CD | 1 |
| Chaudhuri, KR | 1 |
| Rose, S | 2 |
| Jenner, P | 4 |
| Iravani, MM | 2 |
| Lao, CL | 1 |
| Kuo, YH | 1 |
| Hsieh, YT | 1 |
| Chen, JC | 1 |
| Bisht, R | 1 |
| Kaur, B | 1 |
| Gupta, H | 1 |
| Prakash, A | 1 |
| Uchida, S | 1 |
| Soshiroda, K | 1 |
| Okita, E | 1 |
| Kawai-Uchida, M | 1 |
| Mori, A | 1 |
| Kanda, T | 1 |
| Park, G | 1 |
| Park, YJ | 1 |
| Yang, HO | 1 |
| Oh, MS | 1 |
| Millan, MJ | 1 |
| Di Cara, B | 1 |
| Hill, M | 1 |
| Jackson, M | 1 |
| Joyce, JN | 1 |
| Brotchie, J | 1 |
| McGuire, S | 1 |
| Crossman, A | 1 |
| Smith, L | 1 |
| Gobert, A | 1 |
| Peglion, JL | 1 |
| Brocco, M | 1 |
| Stockwell, KA | 1 |
| Virley, DJ | 1 |
| Perren, M | 1 |
| Fukuzaki, K | 1 |
| Kamenosono, T | 1 |
| Kitazumi, K | 1 |
| Nagata, R | 1 |
8 other studies available for ropinirole and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia.
Topics: Adamantane; Animals; Atropine; Benzopyrans; Callithrix; Cholinergic Fibers; Dopamine Agonists; Femal | 2017 |
Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2013 |
Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
Topics: Animals; Ceftriaxone; Encephalitis; Indoles; Male; Motor Activity; MPTP Poisoning; Neuroprotective A | 2014 |
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopa | 2015 |
Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism.
Topics: Animals; Antiparkinson Agents; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Caspase 3; C | 2013 |
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopa | 2004 |
Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Drug Administrati | 2008 |
Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Agonists; Female; Indoles; Levodo | 2000 |